| Serial Number | 79210373 |
| Word Mark | OPTHEA |
| Filing Date | Wednesday, December 7, 2016 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, May 29, 2018 |
| Registration Number | 5477686 |
| Registration Date | Tuesday, May 29, 2018 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 13, 2018 |
| Goods and Services | Biological preparations for pharmaceutical purposes for the treatment of ophthalmic conditions; [ Chemical preparations for pharmaceutical purposes for the treatment of ophthalmic conditions; Chemical products, namely, sugars, proteins and nucleic acids for pharmaceutical use for the treatment of ophthalmic conditions; Chemicals for pharmaceutical use for the treatment of ophthalmic conditions; Pharmaceutical compositions for the treatment of ophthalmic conditions; Pharmaceutical creams for the treatment of ophthalmic conditions; Pharmaceutical drugs for the treatment of ophthalmic conditions; ] Pharmaceutical preparations for the treatment of ophthalmic conditions [ ; Pharmaceutical preparations for animals for the treatment of ophthalmic conditions; Pharmaceutical preparations for human use for the treatment of ophthalmic conditions; Pharmaceutical preparations for personal use for the treatment of ophthalmic conditions; Pharmaceutical preparations for veterinary use for the treatment of ophthalmic conditions; Pharmaceutical products for the treatment of ophthalmic conditions; Pharmaceutical products for use by humans for the treatment of ophthalmic conditions; Pharmaceutical substances for the treatment of ophthalmic conditions; Veterinary medicaments for the treatment of ophthalmic conditions; Veterinary preparations for the treatment of ophthalmic conditions; Veterinary products for the treatment of ophthalmic conditions; Biological preparations for medical purposes for the treatment of ophthalmic conditions; Biological preparations for use in biotechnology for the treatment of ophthalmic conditions; Biological preparations for use in cell cultures, namely in culture media for cultivating human, animal, plant or microorganism cells for medical use; Biological preparations for veterinary purposes for the treatment of ophthalmic conditions; Biological products for medical use, namely for the treatment of ophthalmic conditions; Biological reagents for use in molecular biology for medical use; Biological substances for medical use, namely, biologics, antibodies, monoclonal antibodies, cells and cellular tissues for medical use, namely for the treatment of ophthalmic conditions; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Chemical products, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for use in biology for medical or veterinary use, namely for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Therapeutic biological products, namely, biologics, antibodies, monoclonal antibodies, cells and cellular tissues for medical use, namely for the treatment of ophthalmic conditions; Medical preparations for the treatment of ophthalmic conditions; Substances for use in genetic probe assay kits for medical use, namely, medical diagnostic reagents and assays for testing body fluids; Substances for veterinary use produced by genetic engineering, namely, genetically engineered tissues for transplant purposes; Cultures of cell media for medical use; Cultures of cell media for veterinary purposes; Chemical products for medical or veterinary laboratory use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical preparations for medical analysis purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical preparations for medical purposes for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical preparations for veterinary purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for analysis for medical purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for analysis for veterinary purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for biotechnological purposes for medical uses, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for biotechnological purposes for veterinary use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for medical or veterinary diagnostic purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for medical diagnostic use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for veterinary diagnostic use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions; Chemical products for medical use, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for use in medical science, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemical products for use in science for medical or veterinary purposes, namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions, or, for the treatment of ophthalmic conditions; Chemicals for use in medical and veterinary analysis , namely, biologics, sugars, proteins, nucleic acids and pharmaceuticals for the diagnosis of ophthalmic conditions ] |
| Goods and Services | [ Advisory services relating to scientific research; Laboratory services, namely, scientific research or analysis in the field of ophthalmology; Management of scientific research projects; Medical research and scientific research for medical purposes; Preparation of reports relating to scientific research; Preparation of scientific reports; Providing information, including online, about scientific and technological services and research and design relating thereto, namely for scientific research, analyses and testing in the field of ophthalmology; Provision of information relating to scientific research; Provision of scientific information in the field of ophthalmology; Scientific advisory services in the field of ophthalmology; Scientific analysis in the field of ophthalmology; Technical analysis for research and testing in the field of ophthalmology; Scientific and technological services namely for scientific research, analysis and testing in the field of ophthalmology; Scientific consultancy relating to ophthalmic conditions; Scientific laboratory services; Scientific research; Scientific research in the field of pharmacy; Scientific research into the development of new products; Scientific research relating to bacteriology; Scientific research relating to biology; Scientific research relating to chemical products; Scientific research relating to chemistry; Scientific research relating to genetics; Scientific testing services in the field of ophthalmology; Bacteriological research; Biochemistry research services; Biological research; Biotechnological research; Biotechnology research; Chemical research; Chemical technological research; Genetic research; Laboratory research; Medical research; Pharmaceutical research services; Providing information, including online, about industrial analysis and research services namely for scientific research, analyses and testing in the field of ophthalmology; Provision of medical, veterinary, biological and pharmaceutical research services in the field of ophthalmology; Research and development of new products for others; Research and development of products; Research into the development of new products; Research laboratories in the field of ophthalmology; Research relating to bacteriology; Research relating to biotechnology; Research relating to chemicals; Research relating to chemistry; Research relating to medicine; Research relating to molecular sciences; Research relating to pharmaceuticals; Research relating to science; Research to develop new products; Services for assessing the efficiency of pharmaceuticals namely pharmaceutical product evaluation; Services for assessing the safety of pharmaceuticals, namely testing, inspection or research of pharmaceuticals; Chemical analysis; Laboratory analysis in the field of ophthalmology; Analysis of tissues for medical research; Design of medical apparatus; Medical laboratory services; Analytical laboratory services, namely analysis of tissue samples or bodily fluids for diagnostic purposes; Chemical laboratory services; Laboratory testing services, namely testing of tissue samples or bodily fluids for diagnostic purposes; Veterinary laboratory services; Information in the field of chemical research; Testing of chemicals ] |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 23, 2017 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 23, 2017 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Opthea Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | SOUTH YARRA VIC 3141 AU |
| Party Name | Opthea Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | AU |
| Party Name | Opthea Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | AU |
| Event Date | Event Description |
| Tuesday, June 27, 2017 | APPLICATION FILING RECEIPT MAILED |
| Thursday, June 22, 2017 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, June 23, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, June 23, 2017 | ASSIGNED TO EXAMINER |
| Thursday, June 29, 2017 | NON-FINAL ACTION WRITTEN |
| Friday, June 30, 2017 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, July 6, 2017 | REFUSAL PROCESSED BY MPU |
| Thursday, July 6, 2017 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, July 28, 2017 | REFUSAL PROCESSED BY IB |
| Monday, January 8, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, January 8, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 9, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, February 21, 2018 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, February 21, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, February 6, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 21, 2018 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, September 12, 2018 | FINAL DISPOSITION PROCESSED |
| Friday, September 28, 2018 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Saturday, January 2, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Saturday, December 3, 2022 | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED |
| Friday, March 9, 2018 | NOTIFICATION PROCESSED BY IB |
| Tuesday, March 13, 2018 | PUBLISHED FOR OPPOSITION |
| Tuesday, March 13, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 29, 2018 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, August 29, 2018 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Wednesday, September 12, 2018 | FINAL DISPOSITION NOTICE SENT TO IB |
| Thursday, December 15, 2022 | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Thursday, December 26, 2024 | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Monday, May 29, 2023 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Wednesday, May 22, 2024 | TEAS SECTION 71 RECEIVED |
| Saturday, January 4, 2025 | POST REGISTRATION ACTION MAILED - SEC.71 |
| Monday, July 7, 2025 | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED |
| Monday, July 28, 2025 | POST REGISTRATION ACTION MAILED - SEC.71 |